Development of a novel powder formulation for treatment of idiopathic pulmonary fibrosis
Idiopathic Pulmonary Fibrosis is a progressive, irreversible, ultimately fatal lung disease characterized by restriction in lung capacity, due to scarring of lung tissue. It is estimated that 200,000 to 300,000 people in the western world are affected.
The aim of this study was to develop dry powder formulations for inhalation containing API (Active Pharmaceutical Ingredient) alone and API in combination with coarse carrier particles (lactose monohydrate) for a Phase I first in man clinical study within six months from API delivery.
Recently presented by our expert, Wayne Morley, at Drug Delivery to the Lungs Conference 2017, download your copy of our scientific poster today and discover more.